Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

This study has been completed.
Sponsor:
Collaborator:
HIV Vaccine Trials Network
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00472719
First received: May 11, 2007
Last updated: June 23, 2014
Last verified: June 2014

May 11, 2007
June 23, 2014
August 2007
July 2008   (final data collection date for primary outcome measure)
  • Safety and tolerability of HIV-1 recombinant Clade A env DNA, rAd5, and rAd35 vaccines in participants with pre-existing immunity to Ad5 [ Time Frame: at 9 to 12 months ] [ Designated as safety issue: Yes ]
  • Magnitude and frequency of immune responses between the adenoviral vaccines following DNA prime, assessed by enzyme-linked immunospot (ELISpot) responses, intracellular cytokine staining (ICS) T-cell responses, and HIV-1 antibody assays [ Time Frame: at 4 weeks following fourth vaccination ] [ Designated as safety issue: No ]
  • Immunogenicity of recombinant HIV-1 Clade A env rAd35 vaccine following a recombinant rAd5 prime, assessed by ELISpot responses, ICS T-cell responses, and HIV-1 antibody assays [ Time Frame: at 4 weeks following the second vaccination ] [ Designated as safety issue: No ]
  • Immunogenicity of recombinant HIV-1 Clade A env rAd5 vaccine following a recombinant rAd35, assessed by ELISpot responses, ICS T-cell responses, and HIV-1 antibody assays [ Time Frame: at 4 weeks following the second vaccination ] [ Designated as safety issue: No ]
  • Safety and tolerability of HIV-1 recombinant Clade A env DNA, rAd5, and rAd35 vaccines in participants with pre-existing immunity to Ad5 [ Time Frame: at 9 to 12 months ]
  • Magnitude and frequency of immune responses between the adenoviral vaccines following DNA prime, assessed by enzyme-linked immunospot (ELISpot) responses, intracellular cytokine staining (ICS) T-cell responses, and HIV-1 antibody assays [ Time Frame: at 4 weeks following fourth vaccination ]
  • Immunogenicity of recombinant HIV-1 Clade A env rAd35 vaccine following a recombinant rAd5 prime, assessed by ELISpot responses, ICS T-cell responses, and HIV-1 antibody assays [ Time Frame: at 4 weeks following the second vaccination ]
  • Immunogenicity of recombinant HIV-1 Clade A env rAd5 vaccine following a recombinant rAd35, assessed by ELISpot responses, ICS T-cell responses, and HIV-1 antibody assays [ Time Frame: at 4 weeks following the second vaccination ]
Complete list of historical versions of study NCT00472719 on ClinicalTrials.gov Archive Site
  • Rank of HIV-1 rAd5/rAd35, rAd35/rAd5, DNA/rAd5, and DNA/rAd35 regimens based on ELISpot responses, ICS T-cell responses, and HIV-1 antibody assays [ Time Frame: at 4 weeks after second vaccination for Groups 1 and 2, and at 4 weeks after fourth vaccination for Groups 3 and 4 ] [ Designated as safety issue: No ]
  • Immunogenicity of HIV-1 rAd35 vaccine given as a prime assessed by ELISpot responses, ICS T-cell responses, and HIV-1 antibody assays [ Time Frame: at 4 weeks following first vaccination ] [ Designated as safety issue: No ]
  • Immunogenicity of HIV-1 rAd5 vaccine given as a prime, assessed by ELISpot responses, ICS T-cell responses, and HIV-1 antibody assays [ Time Frame: at 4 weeks following first vaccination ] [ Designated as safety issue: No ]
  • Rank of HIV-1 rAd5/rAd35, rAd35/rAd5, DNA/rAd5, and DNA/rAd35 regimens based on ELISpot responses, ICS T-cell responses, and HIV-1 antibody assays [ Time Frame: at 4 weeks after second vaccination for Groups 1 and 2, and at 4 weeks after fourth vaccination for Groups 3 and 4 ]
  • Immunogenicity of HIV-1 rAd35 vaccine given as a prime assessed by ELISpot responses, ICS T-cell responses, and HIV-1 antibody assays [ Time Frame: at 4 weeks following first vaccination ]
  • Immunogenicity of HIV-1 rAd5 vaccine given as a prime, assessed by ELISpot responses, ICS T-cell responses, and HIV-1 antibody assays [ Time Frame: at 4 weeks following first vaccination ]
Not Provided
Not Provided
 
Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults
A Phase 1B Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenoviral Serotype 35 (rAd35) and Serotype 5 (rAd5) HIV-1 Vaccines When Given in Heterologous Prime-Boost Regimens or as a Boost to a Recombinant DNA Vaccine in Healthy, HIV-1-Uninfected Adult Participants With Pre-Existing Immunity to Adenovirus Serotype 5 Infection

The purpose of this study is to determine the safety of and immune response to an experimental DNA HIV vaccine followed by boosting with either an experimental adenoviral vector HIV vaccine of serotype 5 or 35 in HIV uninfected adults. This study will also determine the safety of and immune response to an adenoviral vector HIV vaccine of serotype 5 followed by a booster of an adenoviral vector of serotype 35, or vice versa, in HIV uninfected adults.

The worldwide HIV/AIDS epidemic may only be controlled through development and utilization of a safe and effective vaccine that will prevent HIV infection. Vaccines using a DNA plasmid to prime the response to an adenoviral vector boost are currently being developed. Due to high prevalence of pre-existing immunity to adenovirus serotype Ad5 in the developing world, this study will evaluate boosting with a different serotype, Ad35, as compared to boosting with the Ad5 serotype. This study will also test the effect of the order of administration of recombinant adenoviral vector HIV vaccines when administered without the DNA plasmid vaccine. Two arms of this study will evaluate the safety and immunogenicity of the experimental multiclade, multigene HIV DNA vaccine VRC-HIVDNA044-00-VP, followed by a similarly structured adenovirus vector vaccine boost (either VRC-HIVADV027-00-VP or VRC-HIVADV038-00-VP), in HIV uninfected adults. To determine the effect of pre-existing Ad5 or Ad35 immunity, the other two arms will test the safety and immunogenicity of receiving either VRC-HIVADV027-00-VP followed by VRC-HIVADV038-00-VP, or vice versa.

Each volunteer will participate in the study for at least 6 months. Participants will be randomly assigned to one of four groups and will receive either an experimental vaccine or placebo at each vaccination visit. Group 1 participants will receive an injection of the adenoviral vector vaccine VRC-HIVADV027-00-VP at study entry and an injection of VRC-HIVADV038-00-VP at Month 3. Group 2 participants will receive an injection of the adenoviral vector vaccine VRC-HIVADV038-00-VP at study entry and an injection of VRC-HIVADV027-00-VP at Month 3. Group 3 participants will receive an injection of the VRC-HIVDNA044-00-VP vaccine at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV027-00-VP at Month 6. Group 4 participants will receive an injection of the DNA HIV vaccine at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV038-00-VP at Month 6.

For Groups 1 and 2, there will be 9 study visits. For Groups 3 and 4, there will be 13 study visits. Medication history, assessment of intercurrent illness and adverse effects, and HIV and pregnancy prevention counseling will occur at all visits. A medical history, a physical exam, HIV testing and counseling and blood and urine collection will occur at selected visits. Participants will also be asked to complete social impact and HIV testing and history questionnaires at selected visits.

As of 11/19/07 enrollment and vaccinations have been discontinued. Participants who have already been enrolled have been told which vaccinations they received and will be followed for a total of 5 years.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Prevention
HIV Infections
  • Biological: VRC-HIVADV027-00-VP
    Adenoviral vector booster vaccine
  • Biological: VRC-HIVADV038-00-VP
    Adenovirus vector booster vaccine
  • Biological: VRC-HIVDNA044-00-VP
    Experimental, multiclade, multigene HIV DNA vaccine
  • Experimental: 1
    Participants in this group will receive an injection of the adenoviral vector vaccine VRC-HIVADV027-00VP at study entry and an injection of VRC-HIVADV038-00-VP at Month 3. There will be 9 study visits for this arm.
    Interventions:
    • Biological: VRC-HIVADV027-00-VP
    • Biological: VRC-HIVADV038-00-VP
  • Experimental: 2
    Participants in this group will receive an injection of VRC-HIVADV038-00-VP at study entry and an injection of VRC-HIVADV027-00-VP at Month 3. There will be 9 study visits for this group.
    Interventions:
    • Biological: VRC-HIVADV027-00-VP
    • Biological: VRC-HIVADV038-00-VP
  • Experimental: 3
    Participants in this group will receive an injection of the VRC-HIVDNA044-00-VP vaccine at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV027-00-VPat Month 6. There will be 13 study visits for this group.
    Interventions:
    • Biological: VRC-HIVADV027-00-VP
    • Biological: VRC-HIVDNA044-00-VP
  • Experimental: 4
    Participants in this group will receive an injection of VRC-HIVDNA044-00-VP at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV038-00-VP at Month 6. There will be 13 study visits for this group.
    Interventions:
    • Biological: VRC-HIVADV038-00-VP
    • Biological: VRC-HIVDNA044-00-VP

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
17
January 2013
July 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • HIV-1 and -2 uninfected
  • Have access to a participating HIV Vaccine Trials Unit (HVTU) and willing to be followed for the duration of the study
  • Willing to receive HIV test results
  • Good general health
  • Pre-existing adenovirus 5 (Ad5) neutralizing antibody titer of 1:1000 ratio or greater
  • Willing to use acceptable forms of contraception from at least 21 days prior to enrollment through the duration of the study

Exclusion Criteria:

  • HIV vaccines in prior HIV vaccine trial
  • Immunosuppressive medications within 168 days prior to first study vaccine administration
  • Blood products within 120 days prior to first study vaccine administration
  • Immunoglobulin within 60 days prior to first study vaccine administration
  • Live attenuated vaccines within 30 days prior to first study vaccine administration
  • Investigational research agents within 30 days prior to first study vaccine administration
  • Subunit or killed vaccines within 14 days prior to first study vaccine administration
  • Current anti-tuberculosis prophylaxis or therapy
  • Clinically significant medical condition, abnormal physical exam findings, abnormal laboratory results, or past medical history that may affect current health. More information about this criterion can be found in the protocol.
  • Any medical, psychiatric, or social condition that would interfere with the study.
  • Serious adverse reaction to vaccines. Participants who have had an adverse reaction to pertussis vaccine as a child are not excluded.
  • Autoimmune disease or immunodeficiency
  • Active syphilis infection. Participants with fully treated syphilis at least 6 months prior to study entry are not excluded.
  • Unstable asthma. More information about this criterion can be found in the protocol.
  • Diabetes mellitus type 1 or 2. Participants with a history of isolated gestational diabetes are not excluded.
  • Absence of thyroid or thyroid disease requiring treatment
  • Serious angioedema within the past 3 years or requiring medication within 2 years of study entry
  • Body mass index (BMI) of 40 or less OR BMI of 35 or less if certain other criteria apply. More information about these criteria can be found in the protocol.
  • Uncontrolled hypertension
  • Bleeding disorder
  • Cancer. Participants with surgically removed cancer that is unlikely to recur are not excluded.
  • Seizure disorder
  • Absence of spleen
  • Certain abnormal laboratory values
  • Mental illness that would interfere with compliance with the protocol
  • Other conditions that, in the judgment of the investigator, would interfere with the study
  • Pregnant or breastfeeding
Both
18 Years to 50 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00472719
HVTN 072, 10517
Yes
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Vaccine Trials Network
Study Chair: Jonathan Fuchs, MD, MPH San Francisco Department of Public Health, University of California, San Francisco
National Institute of Allergy and Infectious Diseases (NIAID)
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP